Biosafety in the preparation and processing of cytology specimens with potential coronavirus (COVID‐19) infection: Perspectives from Taiwan

Chen, Chia Ling; Yu, Chia-Yi

doi:10.1002/cncy.22280

Cited by 54 publications

(102 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, routine laboratory processing pleural effusion, bronchial washings and aspirates, bronchoalveolar lavage, and rinsed transbronchial needle aspiration specimens need centrifugation and/or cytocentrifugation which produces aerosol and causes the most potentially infectious working exposure. Strict biosafety measures should be implemented to prevent accidental or unintentional exposure to infection [55,57]. Several guidelines have been published to help health care workers operate safely in cytology laboratories [21,58].…”

Section: Ancillary Tools: Cytologymentioning

confidence: 99%

Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists

et al. 2020

View full text Add to dashboard Cite

Since its initial recognition in December 2019, Coronavirus disease 19 (COVID-19) has quickly spread to a pandemic infectious disease. The causative agent has been recognized as a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primarily affecting the respiratory tract. To date, no vaccines are available nor any specific treatment. To limit the number of infections, strict directives have been issued by governments that have been translated into equally rigorous guidelines notably for post-mortem examinations by international and national scientific societies. The recommendations for biosafety control required during specimen collection and handling have strongly limited the practice of autopsies of the COVID-19 patients to a few adequate laboratories. A full pathological examination has always been considered an important tool to better understand the pathophysiology of diseases, especially when the knowledge of an emerging disorder is limited and the impact on the healthcare system is significant. The first evidence of diffuse alveolar damage in the context of an acute respiratory distress syndrome has now been joined by the latest findings that report a more complex scenario in COVID-19, including a vascular involvement and a wide spectrum of associated pathologies. Ancillary tools such as electron microscopy and molecular biology used on autoptic tissue samples from autopsy are also significantly contributing to confirm and/or identify new aspects useful for a deeper knowledge of the pathogenetic mechanisms. This article will review and summarize the pathological findings described in COVID-19 until now, chiefly focusing on the respiratory tract, highlighting the importance of autopsy towards a better knowledge of this disease.

show abstract

Section: Ancillary Tools: Cytologymentioning

confidence: 99%

Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Those issues have been raised in recent publications. [32][33][34] For instance, cytopathologists may work in pairs, reducing the time spent on each patient. If possible, after the procedure itself, all sample processing should be performed under a level 2 biosafety hood.…”

Section: B I Osafe T Ymentioning

confidence: 99%

“…The material obtained through the FNA procedure may also be placed in a liquid medium, such as ethanol, enabling cyto-centrifuge preparations, or formaldehyde, enabling the preparation of cell-blocks. [32][33][34] These may be prepared using one of the several methods described in the literature. 35…”

Section: B I Osafe T Ymentioning

confidence: 99%

The role of breast fine needle aspiration during and post‐COVID‐19 pandemic: A fast and safe alternative to needle core biopsy

Gomes

Schmitt

2020

Cytopathology

View full text Add to dashboard Cite

show abstract

“…The main diagnostic clinical samples are nasopharyngeal and/or oropharyngeal swabs, and in severe cases sputum, endotracheal, or bronchoalveolar aspirate. In patients with no respiratory symptoms, stool and feco-anal swabs could be used [7,9,[12][13][14]. Molecular diagnostics is a mainstay of SARS-CoV-2 diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach

Rode

Kurolt

Puljiz

et al. 2020

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

According to anti-SARS-CoV-2 seroresponse in patients with COVID-19 from Croatia, we emphasised the issue of different serological tests and need for combining diagnostic methods for COVID-19 diagnosis. Anti-SARS-CoV-2 IgA and IgG ELISA and IgM/IgG immunochromatographic assay (ICA) were used for testing 60 sera from 21 patients (6 with severe, 10 moderate, and 5 with mild disease). The main clinical, demographic, and haemato-biochemical data were analysed. The most common symptoms were cough (95.2%), fever (90.5%), and fatigue and shortness of breath (42.9%). Pulmonary opacities showed 76.2% of patients. Within the first 7 days of illness, seropositivity for ELISA IgA and IgG was 42.9% and 7.1%, and for ICA IgM and IgG 25% and 10.7%, respectively. From day 8 after onset, ELISA IgA and IgG seropositivity was 90.6% and 68.8%, and for ICA IgM and IgG 84.4% and 75%, respectively. In general, sensitivity for ELISA IgA and IgG was 68.3% and 40%, and for ICA IgM and IgG 56.7% and 45.0%, respectively. The anti-SARS-CoV-2 antibody distributions by each method were statistically different (ICA IgM vs. IgG, p = 0.016; ELISA IgG vs. IgA, p < 0.001). Antibody response in COVID-19 varies and depends on the time the serum is taken, on the severity of disease, and on the type of test used. IgM and IgA antibodies as early-stage disease markers are comparable, although they cannot replace each other. Simultaneous IgM/IgG/IgA anti-SARS-CoV-2 antibody testing followed by the confirmation of positive findings with another test in a two-tier testing is recommended. Keywords COVID-19 diagnostics. Clinical and laboratory findings. Anti-SARS-CoV-2 antibody response. Serological methods. Two-step testing approach. Croatia

show abstract

Biosafety in the preparation and processing of cytology specimens with potential coronavirus (COVID‐19) infection: Perspectives from Taiwan

Cited by 54 publications

References 28 publications

Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists

Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists

The role of breast fine needle aspiration during and post‐COVID‐19 pandemic: A fast and safe alternative to needle core biopsy

Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach

Contact Info

Product

Resources

About